Market News AIOpen the app

Tvardi Therapeutics shared that the FDA gave helpful advice for its new drug TTI-109 for bowel disease.

TrialRead the original at SEC EDGAR
Good for TVRD

Tvardi received FDA feedback supporting its Phase 2 plan and new analysis suggesting TTI-109 may selectively block STAT3. This advances the program, but Phase 2 requires FDA clearance and more funding, and safety in IBD patients is unproven.

TVRD · Tvardi Therapeutics, Inc.

AI read · Good for TVRD

The AI's read

The FDA response gives Tvardi a clearer path to prepare its next study and lets it consider ulcerative colitis and Crohn’s disease. The analysis compares exposure in healthy volunteers with lab measurements. It suggests TTI-109 may block STAT3 while mostly sparing STAT1 and STAT5, but does not prove this effect in patients. Together, these steps move the program forward, but a Phase 2 study still depends on FDA clearance and more funding. Safety in people with inflammatory bowel disease has not been established.

Get alerts for TVRD

Follow Tvardi Therapeutics, Inc. (TVRD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TVRD
Free on the App Store and Google Play, or on the web.